Clouds of Care welcomes the Novalis Biotech Acceleration Fund, a prominent venture capital firm specializing on Life Sciences innovation, to their investor base in a recent €2 million financing round. This extension round also includes renewed support from existing investors, TCD Capital, FFTF (managed by PMV), and White Fund.
Clouds of Care joins the DiMe-led effort together with industry leaders across medical, pharma, biotech, MedTech, regulatory, and patient advocacy groups in advancing the research of a core set of digital endpoints for pediatric rare disease.
The new release of Persyst ESI Powered by Epilog is successfully approved for CE marking for Class IIa devices under the EU Medical Device Regulation. And it doesn't stop there, the approval extends to our QMS system making it simpler and faster for us to bring other Class IIa devices to market.
Over the past 8 years, we’ve advanced over 20 CNS trials with FDA-approved electrophysiology solutions, embraced innovative digital health partnerships, and secured Series A funding—laying the foundation for a transformative, data-driven future in clinical development.
Clouds of Care has secured €5 million in funding, bolstered by the addition of biotech leader Michel Vounatsos as chairman and HealthTech expert Yacine Hadjiat to its board, to accelerate its mission of transforming CNS clinical development with innovative digital health platforms, advanced analytics, and a commitment to improving patient outcomes globally.
To facilitate our growth while maintaining our focus, we are redefining our structure. Introducing Clouds of Care, a holding that will nurture our two dedicated business units: Epilog and Somnilog! Clouds of care will focus on all quality- and regulatory-related aspects of our cloud, software, and infrastructure developments to keep our growth agile in the fast-paced MedTech environment.
We hosted top epilepsy experts to discuss advancements in EEG analysis, including prospective ESI studies, automated ictal ESI validation, and EEG biomarkers for AED effects, concluding with a preview of cutting-edge innovations.
Our 1st symposium focused on advancements and best practices in epilepsy diagnosis and treatment, including EEG, MRI, and case discussions, featuring expert insights on imaging, automation, and epileptogenic networks.
Red Devil, Jan Vertonghen co-invests in Ghent-based scale-up to expand groundbreaking epilepsy AI technology to sleep and other neurological disorders. Epilog, a Medtech company providing brain wave analysis services for clinical practice and clinical trials has raised one million euros to market its Epilog Care technology package worldwide. The Ghent scale-up aims to make it easier to detect and treat epilepsy, sleep problems, and other brain conditions with electroencephalogram (EEG) analysis. Jan Vertonghen, Belgian professional footballer playing for the Belgium national team, who lost his father to epilepsy, is one of the new investors.
Interesting new publication on Electrical Source Imaging of epileptic seizures from our CTO Pieter van Mierlo and friends from Geneva! This review article addresses the importance of localizing the seizure onset zone based on noninvasive EEG recordings as a complementary analysis that might reduce the burden of the presurgical evaluation. Despite the various challenges which have withheld the clinical usage, there are finally new solutions on the horizon bringing Ictal ESI next to Interictal ESI in clinical practice.
For the second year in a row, Epilog proudly announces to be nominated for the Deloitte Rising Star Award, together with 9 other innovative companies. Credits to our amazing Epilog team, our partners and Deloitte!
November is Epilepsy Awareness Month. It's important that more people know about epilepsy and talk about it. With more voices lifted together, we can create greater change. Our Epilog team works every day highly motivated to support epilepsy patients across the globe. Witness their voices in this "corona proof" video! Click on the picture above!
